Disease-modifying antirheumatic Description: Immunomodulators drug (DMARD) therapy for Certolizumab pegol Tocilizumab ▪ ▪ rheumatoid arthritis Description: Immunosuppressive agents (ART) Azathioprine ▪ Cyclosporine ▪ Continued Mycophenolate ▪ Description: kinase (JAK) inhibitor Tofacitinib ▪ Description: Tetracyclines Minocycline ▪ Adult body mass index (BMI) Documented BMI for Physician codes assessment (ABA) outpatient visits in 2016 Weight = 1 or 2017 Codes to identify BMI assessment Percentage of members 18 to Z68.1, Z68.20-39, Z68.41-45, Z68.51 ICD-10-CM diagnosis: – 74 years old who had an Z68.54 outpatient visit and who had a BMI documented during the measurement year or the year prior to the measurement year Note: The weight and BMI must be from the same data source.
Disease-modifying antirheumatic drug (DMARD) therapy for rheumatoid arthritis (ART) Continued Description: Immunomodulators ▪ Certolizumab pegol ▪ Tocilizumab Description: Immunosuppressive agents ▪ Azathioprine ▪ Cyclosporine ▪ Mycophenolate Description: kinase (JAK) inhibitor ▪ Tofacitinib Description: Tetracyclines ▪ Minocycline Adult body mass index (BMI) assessment (ABA) Weight = 1 Percentage of members 18 to 74 years old who had an outpatient visit and who had a BMI documented during the measurement year or the year prior to the measurement year Note: The weight and BMI must be from the same data source. Documented BMI for outpatient visits in 2016 or 2017 Physician codes Codes to identify BMI assessment ICD-10-CM diagnosis: Z68.1, Z68.20-39, Z68.41-45, Z68.51 – Z68.54
2017-Humana-Medicare-HEDIS-Guide.docx